Neurocognitive Functioning in Patients With Newly Diagnosed Upper Aerodigestive Tract Cancer Receiving Treatment at Henry-Joyce Cancer Clinic

Phase

N/A

Condition

Head And Neck Cancer

Non-small Cell Lung Cancer

Lung Cancer

Treatment

N/A

Clinical Study ID

NCT00533884

CDR0000565963

VU-VICC-SUPP-0751

P30CA068485

Ages > 21
All Genders

Study Summary

RATIONALE: Gathering information about how often problems with neurocognitive functioning occur in patients with newly diagnosed upper aerodigestive tract cancers may help doctors learn more about the disease.

PURPOSE: This clinical trial is studying neurocognitive functioning in patients with newly diagnosed upper aerodigestive tract cancers receiving treatment at Henry-Joyce Cancer Clinic.

Eligibility Criteria

Inclusion

DISEASE CHARACTERISTICS:

Newly diagnosed solid tumors of the upper aerodigestive system, including cancers of the head and neck, esophagus, or lung
Receiving treatment at the Henry-Joyce Cancer Clinic at the Vanderbilt-Ingram Cancer Center
No known brain metastasis

PATIENT CHARACTERISTICS:

Able to hear, speak, and understand English
No prior diagnosis of other cancer except basal cell carcinoma

PRIOR CONCURRENT THERAPY:

No treatment plans including prophylactic cranial irradiation

Study Design

October 01, 2007

June 30, 2013

Study Description

OBJECTIVES:

Primary

To establish an estimate of the prevalence of baseline neurocognitive impairment prior to initiation of outpatient cancer treatment.
To establish an estimate of the incidence of neurocognitive impairment during outpatient cancer treatment.
To describe how neurocognitive functioning changes over time during cancer treatment.

Secondary

To identify sociodemographic and clinical factors associated with neurocognitive impairment.
To examine health-related outcomes associated with neurocognitive impairment.

OUTLINE: Patients undergo interview to complete measures of domain-specific neurocognitive functioning, global neurocognitive functioning, subjective neurocognitive functioning, delirium, physical functioning, symptom prevalence and distress, mood states, and medications at baseline before initiation of cancer treatment, at scheduled treatment visits, and at the follow-up visit 3 months after completion of cancer treatment.

Measures of comorbidity, alcohol use, sensory functioning (vision and hearing), and sociodemographic are completed at baseline only. Cancer-related information (diagnosis, staging, and sites of metastasis, if applicable), treatment-related information (planned treatment regimen - chemotherapy and/or radiation therapy), and current medications are obtained at baseline by medical record review.

Health service use and complications are assessed at each scheduled treatment visit and at the 3-month post-treatment follow-up visit. Measures of domain-specific neurocognitive functioning, coping, and quality of life are completed at baseline and at the 3-month follow-up visit.

Connect with a study center

MBCCOP - Meharry Medical College - Nashville
Nashville, Tennessee 37208
United States
Site Not Available
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee 37232-6838
United States
Site Not Available
Vanderbilt-Ingram Cancer Center - Cool Springs
Nashville, Tennessee 37064
United States
Site Not Available
Vanderbilt-Ingram Cancer Center at Franklin
Nashville, Tennessee 37064
United States
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.